BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 23462184)

  • 1. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
    Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
    Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
    Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
    Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
    Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
    Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
    Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S; Lowe M; Herliczek TW; Keyomarsi K
    Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
    Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM
    Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
    Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
    Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities.
    He G; Siddik ZH; Huang Z; Wang R; Koomen J; Kobayashi R; Khokhar AR; Kuang J
    Oncogene; 2005 Apr; 24(18):2929-43. PubMed ID: 15735718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.